Corline’s Renaparin™ is administered by flushing the vessel system of the kidney ex vivo prior to transplantation, and repairs the damaged blood vessel system. RenaparinTM thus protects kidneys from the innate immune response and has been shown to significantly decrease reperfusion injury in pre-clinical models.
Corline® has been granted orphan drug designation in the EU for Renaparin™.